Use your browser's back button to choose another title or click here for a New Search.

How to Get the Poster

 Open slide (ppt)




Bookmark and Share

NIDA Clinical Trials Network: Examples of Community Program Buprenorphine Dissemination in Low-Access Areas.

Poster presented at the American Academy of Addiction Psychiatry (AAAP) annual meeting, Boca Raton, FL, December 2-5, 2010.

Hilary Smith Connery, MD, PhD (McLean Hospital, NEC Node), Mark Publicker, MD (Mercy Recovery Center, NEC Node), Jim Hoyne, DO (Douglas Medical Clinic, WS Node), Allison Cohen (McLean Hospital, NEC Node), Scott Provost, MM, MSW (McLean Hospital, NEC Node), George E. Woody, MD (Treatment Reserach Institute, DV Node), Roger D. Weiss, MD (McLean Hospital, NEC Node).

Knudsen and colleagues (2009) described adoption of buprenorphine treatment (BUP) doubling in community-based treatment programs (CTPs) within the National Drug Abuse Treatment Clinical Trials Network (CTN) during the first two years of CTP participation (2002-2004) regardless of whether or not CTPs participated directly in a buprenorphine protocol, supporting community partnerships for accelerating dissemination of evidence-based practices. Barriers to wider buprenorphine dissemination persist; availability may be limited by physician access, patient characteristics, attitudinal or institutional factors, state/local policies, and Medicaid reimbursement. This poster reports on two CTP physicians' efforts to introduce or expand BUP in communities where access to BUP was limited.

IRB approval was obtained for a 13-item self-report telephone interview with two CTP physician site PIs who participated in a CTN buprenorphine protocol and later successfully sustained expanded access to BUP in CTPs with barriers of rural location and/or few qualified buprenorphine-prescribing physicians. The interview was designed and conducted by another CTP physician who participated in CTN buprenorphine protocols. Both physicians reported: 1) high local prevalence of opioid dependence, especially among youth; 2) mostly maintenance treatment in adults and youth; 3) local resistance to BUP in youth despite evidence supporting better outcomes; 4) cost of treatment and poor reimbursement by state Medicaid insurances as the main barrier to patient access and physician/program adoption. In conclusion, it appears that lack of insurance reimbursement and prevailing community beliefs regarding buprenorphine maintenance for opioid dependence (particularly for youth) remain barriers to wider practice dissemination. (Poster, PowerPoint slides, English, 2010)

Keywords: Adolescents | Adoption of interventions | Buprenorphine | Community health services | CTN platform/ancillary study | Dissemination | Medicaid | Opioid dependence | Pharmacological therapy | Research participation | American Academy of Addiction Psychiatry (AAAP) annual meeting, 2010

Document No: 660

Submitted by Hilary Smith Connery, MD, PhD, McLean Hospital, NEC Node, 3/1/2011.

Cohan, Allison search  
Connery, Hilary Smith search mail
Hoyne, Jim search
Provost, Scott E. search mail
Publicker, Mark search
Weiss, Roger D. search mail
Woody, George E. search mail
Delaware Valley search www
New England Consortium search www
Western States search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 3/2011 --